Market Overview

UPDATE: Benchmark Raises PT on Cardiovascular Systems on Fiscal 2014 Estimates

Related CSII
Abaxis (ABAX) Soars: Stock Rises 9% - Tale of the Tape
Halozyme's Q1 Loss Widens - Analyst Blog

In a report published Friday, Benchmark Company analyst James Terwilliger reiterated his Speculative Buy rating on Cardiovascular Systems (NASDAQ: CSII), and raised his price target from $18.00 to $24.00.

In the report, Terwilliger noted, “We are publishing our fiscal 2014 revenue and EPS estimates of $125 million and ($0.78). This represents 25% revenue growth compared to our fiscal 2013 revenue estimate of $100 million. Our fiscal 2014 EPS estimate of ($0.78) compares favorably to our fiscal 2013 EPS estimate of ($1.09). The main driver of the improvement in our bottom line results is our assumption that CSII receives regulatory approval for their cardiology application with a subsequent launch in Q1:14 of calendar 2014.”

Cardiovascular Systems closed on Thursday at $20.30.

Posted-In: Benchmark CompanyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (CSII)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters